Immune Checkpoint Inhibitors in Oncology: Pembrolizumab (Keytruda)

Share on email
Share on print
Share on whatsapp

Tumours harness several strategies to avoid elimination by the immune system and exploiting the programmed cell death protein (PD1) is a key component. Studies have shown that the expression of PD1 by tumour-infiltrating lymphocytes is . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading